Company Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Stephan Jackman |
Contact Details
Address: 3500 Lenox Rd. Ne, Suite 1500 Atlanta, Georgia 30326 United States | |
| Phone | 844-722-6333 |
| Website | alzamend.com |
Stock Details
| Ticker Symbol | ALZN |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001677077 |
| CUSIP Number | 02262M308 |
| ISIN Number | US02262M4078 |
| Employer ID | 81-1822909 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephan Jackman | Chief Executive Officer and Director |
| David J. Katzoff | Chief Financial Officer |
| Milton Charles Ault III | Founder and Vice Chairman |
| Henry C. W. Nisser Esq. | Executive Vice President, General Counsel and Director |
| Kenneth S. Cragun CPA | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 25, 2024 | 10-Q | Quarterly Report |
| Mar 25, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 18, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Mar 13, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 2, 2024 | 8-K | Current Report |